Ironwood Pharmaceuticals Stock Today

IRWD Stock  USD 8.71  0.09  1.04%   

Performance

0 of 100

 
Low
 
High
Very Weak

Odds Of Distress

Over 58

 
100  
 
Zero
Above Average
Ironwood Pharmaceuticals is trading at 8.71 as of the 29th of March 2024, a 1.04% increase since the beginning of the trading day. The stock's lowest day price was 8.59. Ironwood Pharmaceuticals has over 58 % chance of experiencing financial distress in the next 2 years of operation and has generated negative returns for investors over the last 90 days. Equity ratings for Ironwood Pharmaceuticals are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 29th of January 2024 and ending today, the 29th of March 2024. Click here to learn more.
Business Domain
Pharmaceuticals, Biotechnology & Life Sciences
IPO Date
3rd of February 2010
Category
Healthcare
Classification
Health Care
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal products. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts. Ironwood Pharmaceuti operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. The company has 156.53 M outstanding shares of which 18.77 M shares are currently shorted by private and institutional investors with about 2.46 trading days to cover. More on Ironwood Pharmaceuticals

Moving together with Ironwood Stock

  0.62MBIO Mustang Bio Report 3rd of April 2024 PairCorr
  0.72KA Kineta Inc Financial Report 9th of May 2024 PairCorr

Moving against Ironwood Stock

  0.86YS YS Biopharma Report 22nd of April 2024 PairCorr
  0.75MDGL Madrigal Pharmaceuticals Financial Report 14th of May 2024 PairCorr
  0.66DNLI Denali Therapeutics Financial Report 13th of May 2024 PairCorr
  0.62MDWD Mediwound Downward RallyPairCorr
  0.54MESO Mesoblast TrendingPairCorr

Ironwood Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Ironwood Pharmaceuticals' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Ironwood Pharmaceuticals or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
CEO, DirectorMark Mallon
Thematic IdeaObamacare Repeal (View all Themes)
Business ConcentrationBiotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, SP Small-Cap 600, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Composite Total, NASDAQ Health Care, Obamacare Repeal, Health Care, Biotechnology, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors)
Average Analyst Recommendation
Analysts covering Ironwood Pharmaceuticals report their recommendations after researching Ironwood Pharmaceuticals' financial statements, talking to executives and customers, or listening in on Ironwood Pharmaceuticals' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Ironwood Pharmaceuticals. The Ironwood consensus assessment is calculated by taking the average forecast from all of the analysts covering Ironwood Pharmaceuticals.
Ironwood Pharmaceuticals' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Ironwood Pharmaceuticals' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Ironwood Pharmaceuticals' bond ratings measure its overall creditworthiness, which in many ways corresponds to the cost of borrowing for an issuer. These ratings assign a letter grade to all of Ironwood Pharmaceuticals' outstanding corporate bonds that indicate their credit quality. We use reports published by private self-sufficient rating services such as Standard & Poor's or Fitch Ratings Inc. to evaluate a bond issuer's financial strength or its ability to pay a bond's principal and interest.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Ironwood Pharmaceuticals' financial leverage. It provides some insight into what part of Ironwood Pharmaceuticals' total assets is financed by creditors.
By using current balance sheet information, investors can analyze the liability, assets, and equity on Ironwood Pharmaceuticals' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Ironwood Pharmaceuticals deploys its capital and how much of that capital is borrowed.
Liquidity
Ironwood Pharmaceuticals cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 715.54 M in liabilities with Debt to Equity (D/E) ratio of 0.78, which is about average as compared to similar companies. Ironwood Pharmaceuticals has a current ratio of 25.99, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Ironwood Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Ironwood Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Ironwood Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Ironwood to invest in growth at high rates of return. When we think about Ironwood Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Stock Based Compensation

23.83 Million
Ironwood Pharmaceuticals (IRWD) is traded on NASDAQ Exchange in USA. It is located in 100 Summer Street, Boston, MA, United States, 02110 and employs 267 people. Ironwood Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.35 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Ironwood Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Ironwood Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Ironwood Pharmaceuticals conducts business under Biotechnology sector and is part of Health Care industry. The entity has 156.53 M outstanding shares of which 18.77 M shares are currently shorted by private and institutional investors with about 2.46 trading days to cover. Ironwood Pharmaceuticals currently holds about 504.36 M in cash with 183.43 M of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.29.
Check Ironwood Pharmaceuticals Probability Of Bankruptcy
Ownership Allocation
Ironwood Pharmaceuticals secures a total of 156.53 Million outstanding shares. The majority of Ironwood Pharmaceuticals outstanding shares are owned by outside corporations. These institutional investors are usually referred to as non-private investors looking to purchase positions in Ironwood Pharmaceuticals to benefit from reduced commissions. Consequently, third-party entities are subject to a different set of regulations than regular investors in Ironwood Pharmaceuticals. Please pay attention to any change in the institutional holdings of Ironwood Pharmaceuticals as this could imply that something significant has changed or is about to change at the company. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
Check Ironwood Ownership Details

Ironwood Stock Price Odds Analysis

What are Ironwood Pharmaceuticals' target price odds to finish over the current price? Based on a normal probability distribution, the odds of Ironwood Pharmaceuticals jumping above the current price in 90 days from now is about 91.2%. The Ironwood Pharmaceuticals probability density function shows the probability of Ironwood Pharmaceuticals stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Ironwood Pharmaceuticals has a beta of 0.2259. This usually indicates as returns on the market go up, Ironwood Pharmaceuticals average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Ironwood Pharmaceuticals will be expected to be much smaller as well. Additionally, ironwood Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming NYSE Composite.
  Odds Below 8.71HorizonTargetOdds Above 8.71
8.76%90 days
 8.71 
91.20%
Based on a normal probability distribution, the odds of Ironwood Pharmaceuticals to move above the current price in 90 days from now is about 91.2 (This Ironwood Pharmaceuticals probability density function shows the probability of Ironwood Stock to fall within a particular range of prices over 90 days) .

Ironwood Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Ironwood Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Ironwood Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Ironwood Pharmaceuticals' value.
InstituionRecorded OnShares
Geode Capital Management, Llc2023-12-31
3.1 M
Jacobs Levy Equity Management, Inc.2023-09-30
2.4 M
Jupiter Asset Management Limited2023-12-31
2.3 M
Goldman Sachs Group Inc2023-12-31
2.2 M
Morgan Stanley - Brokerage Accounts2023-12-31
2.1 M
Nuveen Asset Management, Llc2023-12-31
1.8 M
Northern Trust Corp2023-12-31
1.6 M
Driehaus Capital Management Llc2023-12-31
1.6 M
Adage Capital Partners Gp Llc2023-12-31
1.5 M
Blackrock Inc2023-12-31
26 M
Sarissa Capital Management Lp2023-09-30
16.4 M
View Ironwood Pharmaceuticals Diagnostics

Ironwood Pharmaceuticals Historical Income Statement

Ironwood Pharmaceuticals Income Statement is one of the three primary financial statements used for reporting Ironwood's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Ironwood Pharmaceuticals revenue and expense. Ironwood Pharmaceuticals Income Statement primarily focuses on the company's revenues and expenses during a particular period.
At present, Ironwood Pharmaceuticals' Operating Income is projected to increase significantly based on the last few years of reporting. The current year's EBIT is expected to grow to about 219.5 M, whereas Interest Expense is forecasted to decline to about 19.9 M. View More Fundamentals

Ironwood Stock Against Markets

Picking the right benchmark for Ironwood Pharmaceuticals stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Ironwood Pharmaceuticals stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Ironwood Pharmaceuticals is critical whether you are bullish or bearish towards Ironwood Pharmaceuticals at a given time. Please also check how Ironwood Pharmaceuticals' historical prices are related to one of the top price index indicators.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Ironwood Pharmaceuticals without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Performance Analysis Now

   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Module

Ironwood Pharmaceuticals Corporate Directors

Ironwood Pharmaceuticals corporate directors refer to members of an Ironwood Pharmaceuticals board of directors. The board of directors generally takes responsibility for the Ironwood Pharmaceuticals' affairs and long-term direction of the entity. A corporate director does not make decisions for the corporation on his own. As a member of the board of directors, she or he must function as a part of a group that makes decisions on behalf of the business only by the board of directors' meetings. To pass a resolution, a majority of Ironwood Pharmaceuticals' board members must vote for the resolution. The Ironwood Pharmaceuticals board of directors' duties also include the election, removal, and supervision of officers, including the adoption, amendment, and repeal of bylaws.
Julie McHughIndependent DirectorProfile
Christopher WalshIndependent DirectorProfile
Lawrence OlanoffDirectorProfile
Matt RoacheDirector RelationsProfile

How to buy Ironwood Stock?

Before investing in Ironwood Pharmaceuticals, you must ensure you fully understand your financial goals and how diversified (or not) your overall investments are now. Then, after you clearly understand your investment objectives, consider investing in Ironwood Pharmaceuticals. To buy Ironwood Pharmaceuticals stock, you can follow these steps:
  • Choose a brokerage firm: You need to select a brokerage firm to buy shares of Ironwood Pharmaceuticals. Some popular options include Charles Schwab, Fidelity, TD Ameritrade, and Robinhood.
  • Open an account: Once you have chosen a brokerage firm, you will need to open an account. You will be required to provide personal information, such as your name, address, and Social Security number.
  • Fund your account: You will need to deposit funds into your brokerage account to purchase Ironwood Pharmaceuticals stock. You can do this by transferring funds from your bank account or other investment accounts.
  • Place your order: Once you have located Ironwood Pharmaceuticals stock in your brokerage account, you can place your order to buy it. You will need to specify the number of shares you want to buy and the price you are willing to pay.
  • Monitor your investment: After you have purchased Ironwood Pharmaceuticals stock, you should monitor your investment to track its performance and make informed decisions about buying, selling, or holding the stock
It's important to note that investing in stocks, such as Ironwood Pharmaceuticals, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember various factors, including economic indicators, change in net worth, political events, company-specific news, and investor sentiment, can influence the stock market. These factors can cause fluctuations in stock prices and lead to market volatility affecting your buy or sell decision. However, volatility can also present opportunities for investors to make gains by buying stocks when prices are low and selling when they are high. It's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. For more information on how to buy Ironwood Stock please use our How to Invest in Ironwood Pharmaceuticals guide.

Already Invested in Ironwood Pharmaceuticals?

The danger of trading Ironwood Pharmaceuticals is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Ironwood Pharmaceuticals is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Ironwood Pharmaceuticals. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Ironwood Pharmaceuticals is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Ironwood Pharmaceuticals is a strong investment it is important to analyze Ironwood Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Ironwood Pharmaceuticals' future performance. For an informed investment choice regarding Ironwood Stock, refer to the following important reports:
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Ironwood Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in housing.
For information on how to trade Ironwood Stock refer to our How to Trade Ironwood Stock guide.
You can also try the Options Analysis module to analyze and evaluate options and option chains as a potential hedge for your portfolios.

Complementary Tools for Ironwood Stock analysis

When running Ironwood Pharmaceuticals' price analysis, check to measure Ironwood Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ironwood Pharmaceuticals is operating at the current time. Most of Ironwood Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Ironwood Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ironwood Pharmaceuticals' price. Additionally, you may evaluate how the addition of Ironwood Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Ironwood Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ironwood Pharmaceuticals. If investors know Ironwood will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ironwood Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.69)
Earnings Share
(6.45)
Revenue Per Share
2.848
Quarterly Revenue Growth
0.097
Return On Assets
0.1339
The market value of Ironwood Pharmaceuticals is measured differently than its book value, which is the value of Ironwood that is recorded on the company's balance sheet. Investors also form their own opinion of Ironwood Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Ironwood Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ironwood Pharmaceuticals' market value can be influenced by many factors that don't directly affect Ironwood Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ironwood Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Ironwood Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ironwood Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.